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The effects of atenolol (A) 50 mg, slow release nifedipine (N) 20 
mg, and their combination(AN) given 12 hourly, on myocardial ischemia 
were studied in 23 patients with stable angina pectoris, documented core- 
nary artery disease and a positive exercise test in a randomized, double 
blind, three way, cross over study. A treadmill exercise test and 24-hour 
ambulatory electrocardiogra@ic monitoring were obtained after a period 
of 5 days off-therapy (control) and at the end of 3 weeks of each treat- 
mart period. Compared to control, N induced an increase in resting heart 
rate of 14ti bpm (pcO.OOl), while A and AN rduck.3 ib by 24~2 and 2Oi1 
bpm respectively @cO.OOl). The number of exercise tests rendered nega- 
tive after each intervention was 5,9, and 11 for N, A and AN respec- 
tively. Compared to control the time to onset 06 myocardial ischemia (1 
mm ST-segment depression) during exercise significantly (pcO.001) in- 
creased compared to control by 3.2ti.6 min after N, by 4.6t0.4 min after A, 
and by 4.6t0.5 min after AN; Rate-pressure product (bpt mmHg) at I mm 
ST-segment depression increased by 2824970 (pcO.01) after N but full 
(pcO.001) by 4436t900 and 4SOk719 after A and AN respectively. The 
total ischemic time during ambulatory monitoring was reduced from 
69a17 min during control to 37.54.8 min during N (pcO.01 vs control) to 
1563.5 min during A (pcO.01 vs control and N) and to 6.53.7 min during 
AN (~~0.01 vs control and N, PcO.05 vs A). 
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Cholestyramine (Ql) and lovastatin (MEV) are effective 
LOL-cholesterol (LDL-C) lowering agents. The purpose of 
this study was to demonstrate the efficacy of these two 
agents when used in combination, Preliminary data from 
133 hypercholesterolemic patients (mean age 56.8210.7 
years) with LDL-C levels a160 mg/dl after six weeks 
treatment on 16gm/day QL and a low-cholesterol diet were 
randomized to five treatment groups. The daily dosages 
of each were: 1) continuation 16gm Ql; 2) 16gm Ql plus 
2thng MEV; 3) 16gm Ql plus 40mg MEV; 4) 8gm QL plus 
20mg MEV; and 5) 40mg MEV. Following eight weeks of 
treatment post-randomization, percent decreases in total 
cholesterol (%AC) and LDL-C (%AlDl-C) SEM were the 
following: 
N %AC %AlDL-C 
16gm Ql 27 17.6k2.2 
16gm Ql + 20mg MEV 
28.8k3.3 
16gm Ql + 40mg MEV 22: 
35. bl.6 50.9&l .8 
8gm Ql + 
38.1kl.7 55.1k1.8 
35 
40 mg MEV 
20mg MEv 29.9A1.4 44.5k1.6 
14 29.2*2.0 40.7k2.2 
Fewer GI side effects and/or liver enzyme ?lpvations 
were. qoted in the 8gm Ql + 2Chng MEV group. These 
preliminary results indicate that the combination of 
lower doses of Ql and MEV result in marked lowering of 
total cholesterol and LDL-C without as many of the GI 
side effects and/or liver function abnormalities seen 
with higher doses of single or combination therapies. 
Thus, the undesirable effect of high basal heart rate induced by N 
is neutralised by its combination with A. Whereas A and AN are equally 
efficacious in controlling exercise induced ischemia, AN was more effec- 
tive in reducing total ischemic burden. 
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The role of converting enzyme inhibition in angina is controversial. 
We compared the effects of placebo (P). benazepril 1Omg bd (B), 
nifedipine retard 20 mg bd (N) and their combination (B+N) in a 
random order, case controlled trial of 34 patients with uncomplicated 
chronic stable angina. Each treatment phase was of two weeks 
duration and exercise testing was performed using a Bruce treadmill 
exercise protocol. 
N increased exercise time to lmm ST depression (4.2 f 0.3 10 5.0 _+ 
0.3 min, P and N respectively. p ~0.05). B and B+ N had a lesser 
benefit (4.4 f 0.2 and 4.7 f 0.3 min. B and B+N respectively. NS). 
Sixteen of the 34 patients increased exercise time to Imm ST 
depression with B. These patients were identified by a higher 30 
minute supine renin level (0.8 f 0.8 vs 0.4 +, 0.2 nmollllhr. 
PCO.05). 
No significant difference was observed in sublingual nitrate 
consumption or number of angina1 attacks between any of the 
treatments. 
Con;htsions, 
1. Benazepril has a small effect in preventing exercise induced angina 
but is less effective than nifedipine. 
2. The benefit of benazepril appears gre3tp.r in patients with higher 
resting renin levels. 
3. A combination of benazepril and nifedipine appears to offer no 
advantage over nifedipine alone. 
